StockData

Alumis vs Zenas BioPharma

ALMS and ZBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALMS and ZBIO compare

Zenas BioPharma is the larger company, worth 2.9 times as much as Alumis ($1.8B against $626M).

Alumis scores higher on the StockData Score (6 against 1 for Zenas BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALMSZBIO
Size and price
Market cap$626M$1.8B
Share price$4.84$27.75
Change, 1 year−12.3%−20.7%
Beta (5Y)2.170.25
Employees224167
StockData Score
Total score6 (better)1
Valuation score1 (better)0
Growth score00
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S84.7×–
P/B1.4× (better)8.5×
FCF yield−56.2%−13.4% (better)
Profitability
Operating margin−6204%–
Net margin−5933%–
FCF margin−4755%–
Return on equity−93.6% (better)−265%
Financial health
Debt / equity0.001.05 (better)
Current ratio6.749.42 (better)
Altman Z-score−1.13 (better)−1.48
Piotroski F-score2 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions91.3%94.0%
Held by insiders30.5%36.1%
Insider net buying, 12 months$44.7M (better)$11.4M
Short interest, % of float12.3%27.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.